Skip to main content
SpringerLink
Log in

Pharmaceuticals for Bone Disease Targeting the Osteoclast

  • Chapter
Bone Resorption

Part of the book series: Topics in Bone Biology ((TBB,volume 2))

  • 1021 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexandersen P, Riis BJ, Stakkestad JA, Delmas PD, Christiansen C (2001) Efficacy of levormeloxifene in the prevention of postmenopausal bone loss and on the lipid profile compared to low dose hormone replacement therapy. JCEM 86:755–60.

    PubMed  CAS  Google Scholar 

  2. Anonymous (1996) Effects of hormone therapy on BMD: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The writing group for the PEPI. Journal of the American Medical Association 276:1389–96.

    Article  Google Scholar 

  3. Astrom E, Soderhall S (2002) Beneficial effect of long-term intravenous bisphosphonates treatment of osteogenesis imperfecta. Arch Dis Child 86:356–64.

    Article  PubMed  CAS  Google Scholar 

  4. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. JBMR 19:1059–66.

    Article  CAS  Google Scholar 

  5. Bergstrom JD, Bostedor RG, Masarachia PJ et al (2000) Alendronate is a specific, nanomolar inhibitior of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231–41.

    Article  PubMed  CAS  Google Scholar 

  6. Bianchi ML, Cimaz R, Bardare M, et al. (2000) Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study. Arthritis Rheum 43: 1960–6.

    Article  PubMed  CAS  Google Scholar 

  7. Black DM, Greenspan SL, Ensrud KE, Palermo L, et al. (2003) The effects of PTH and alendronate alone or in combination in postmenopausal osteoporosis. NEJM 349(13):1207–15.

    Article  PubMed  CAS  Google Scholar 

  8. Black DM, Cummings SR, Karpf DB, Cauley JA, et al. (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. The Lancet 348:1535–41.

    Article  CAS  Google Scholar 

  9. Bone HG, Hosking D, Devogelaer JP, Tucci JR, et al. (2004) Ten years’ experience with alendronate for osteoporosis in postmenopausal women. NEJM 350(12): 1189–99.

    Article  PubMed  CAS  Google Scholar 

  10. Brumsen C, Hamdy NA, Papapoulos SE (1997) Long-term effects of bisphosphonates on the growing skeleton. studies of young patients with severe osteoporosis. Medicine (Baltimore) 76:2166–83.

    Article  Google Scholar 

  11. Chavassieux PM, Arlot ME, Reda C, Wei L, et al. (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475–80.

    Article  PubMed  CAS  Google Scholar 

  12. Chesnut CH, III, Silverman S, Andriano K, et al. (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. American Journal of Medicine 109:267–76.

    Article  PubMed  CAS  Google Scholar 

  13. Cosman F, Nieves J, Woelfert L, et al. (2001) PTH added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after PTH withdrawal. JBMR 16(5):925–32.

    Article  CAS  Google Scholar 

  14. Cosman F, Nieves J, Woelfert L, et al. (1998) Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. JBMR 13(6):1051–5.

    Article  CAS  Google Scholar 

  15. Cranney A, Tugwell P, Wells G, Guyatt G, et al. (2002) Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocrine Reviews 23(4):497–507.

    CAS  Google Scholar 

  16. Cranney A, Wells G, Willan A, Griffith L, et al. (2002) Meta-analysis of alendronate for the treatment of postmenopausal women. Endocrine Reviews 23(4): 508–16.

    Article  PubMed  CAS  Google Scholar 

  17. Cranney A, Tugwell P, Adachi J, Weaver B, et al. (2002) Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Reviews 23(4): 517–23.

    Article  PubMed  CAS  Google Scholar 

  18. Cranney A, Tugwell P, Zytaruk N, Robinson V, et al. (2002) Meta-analysis of raloxifene for the prevention and treatment of osteoporosis. Endocrine Reviews 23(4):524–8.

    Article  PubMed  CAS  Google Scholar 

  19. Cranney A, Tugwell P, Zytaruk N, Robinson V, et al. (2002) Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine Reviews 23(4):540–51.

    Article  PubMed  CAS  Google Scholar 

  20. Cranney A, Guyatt G, Griffith L, Wells G, et al. (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocrine Reviews 23(4): 570–8.

    Article  PubMed  CAS  Google Scholar 

  21. Delmas PD, Recker RR, Chestnut CH, et al. (2004) Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis International 15:792–8.

    Article  PubMed  CAS  Google Scholar 

  22. Eastell R, Adachi J, Harper K, Sarkar S, Delmas PD, Ensrud K, et al. (2000) The effects of raloxifene on incident vertebral fractures in postmenopausal women with osteoporosis: 4-year results from the MORE trial. JBMR 15:S229.

    Article  Google Scholar 

  23. Ettinger B, San Martin J, Crans G, and Pavo I (2004) Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. JBMR 19(5):745–51.

    Article  CAS  Google Scholar 

  24. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. (1999) Reduction of vertebral fractures in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized trial. JAMA 282:637–45.

    Article  PubMed  CAS  Google Scholar 

  25. Ettinger B, Pressman A, Silver P (1999) Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause 6:289.

    Article  Google Scholar 

  26. Ettinger M, Schwartz E, Emkey R, Moffett AF, et al. Lasofoxifene, a next generation selective estrogen receptor modulator (SERM), in the prevention of bone loss in postmenopausal women. The Endocrine Society’s 86th Annual Meeting, New Orleans, LA, June 14–19, 2004: Abstract S35-2.

    Google Scholar 

  27. www.fda.gov

    Google Scholar 

  28. Field CS, Ory SJ, Wahner HW, Herrmann RR, et al. (1993) Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 168:114–21.

    PubMed  CAS  Google Scholar 

  29. Filipponi P, Cristallini S, Rizzello E, Policani G, et al. (1996) Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone 18:179–84.

    Article  PubMed  CAS  Google Scholar 

  30. Finkelstein J, Hayes A, Hunzelman J, et al. (2003) The effects of PTH, alendronate, or both in men with osteoporosis. NEJM 349(13):1216–26.

    Article  PubMed  CAS  Google Scholar 

  31. Gallagher JC (2001). Role of estrogens in the management of postmenopausal bone loss. Rheum Dis Clin North Am 27:143–62.

    Article  PubMed  CAS  Google Scholar 

  32. Giannini S, D’Angelo A, Sartori L. Passeri G, et al. (1996) Continuous and cyclical clondronate therapies and bone density in postmenopausal bone loss. Obstet Gynecol 88:431–6.

    Article  PubMed  CAS  Google Scholar 

  33. Glorieux FH, Bishop NJ, Plotkin H, et al. (1998) Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. NEJM 339:947–52.

    Article  PubMed  CAS  Google Scholar 

  34. Greendale GA, Wells B, Marcus R, Barrett-Connor E (2000) How many women lose BMD while taking hormone replacement therapy? Results from the postmenopausal estrogen/progestin interventions trial. Arch Intern Med 160:3065–71.

    Article  PubMed  CAS  Google Scholar 

  35. Greenspan SL, Resnick NM, and Parker RA (2003) Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women. JAMA 289(19):2525–33.

    Article  PubMed  CAS  Google Scholar 

  36. Greenspan SL, Emkey RD, Bone HG, Weiss SR, et al. (2002) Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Intern Med 137:875–83.

    PubMed  CAS  Google Scholar 

  37. Harris ST, Watts NB, Genant HK, McKeever CD, et al. (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282(14):1344–52.

    Article  PubMed  CAS  Google Scholar 

  38. Heaney RP, Saville PD (1976). Etidronate disodium in postmenopausal osteoporosis. Clin Pharm Therap 20: 593–604.

    PubMed  CAS  Google Scholar 

  39. Ibrahim A, Scher N, Williams G, Sridhara R, et al. (2003) Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clinical Cancer Research. 9(7):2394–9.

    PubMed  CAS  Google Scholar 

  40. Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, et al. (2000) Long-term effects of raloxifene on BMD, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444–50.

    Article  PubMed  CAS  Google Scholar 

  41. Khosla S (2003) PTH plus alendronate — a combination that does not add up. NEJM 349(13):1277–9.

    Article  PubMed  Google Scholar 

  42. Kostenuik PJ and Shalhoub V (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Current Pharmaceutical Design 7(8):613–35.

    Article  PubMed  CAS  Google Scholar 

  43. Kousteni S, Han L, Chen J, Almeida M, Plotkin LI, et al. (2003) Kinase-mediated regulation of common transcription factors accounts for the bone-protective effects of sex steroids. Journal of Clinical Investigation 111(11):1651–64.

    Article  PubMed  CAS  Google Scholar 

  44. Lehenkari PP, Kellinsalmi M, Napankangas JP, et al. (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255–62.

    Article  PubMed  CAS  Google Scholar 

  45. Lieberman UA, Weiss SR, Bröll J, Minne HW, et al. (1995) Effect of oral alendronate on BMD and the incidence of fractures in postmenopausal osteoporosis. NEJM 333(22):1437–43.

    Article  Google Scholar 

  46. Lindsay R, Nieves J, Formica C, et al. (1997) Randomised controlled study of effect of PTH on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. The Lancet 350:550–5.

    Article  CAS  Google Scholar 

  47. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. (1992) Effects of tamoxifen on BMD in postmenopausal women with breast cancer. NEJM 326:852–6.

    PubMed  CAS  Google Scholar 

  48. Luckman SP, Hughes DE, Coxon FP, et al. (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. JBMR 13:581–9.

    Article  CAS  Google Scholar 

  49. Lufkin EG, Riggs LB (1996) Three-year follow up on effects of transdermal estrogen. Ann Intern Med 125(1):77.

    PubMed  CAS  Google Scholar 

  50. Lufkin EG, Wahner HW, O’Fallon WM, Hodgson SF, et al. (1992) Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117(1):1–9.

    PubMed  CAS  Google Scholar 

  51. Marcus R, Holloway L, Wells B, Greendale G, James MK, Wasilauskas C, et al. (1999) The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JBMR 14:1583–95.

    Article  CAS  Google Scholar 

  52. Markowitz GS, Appel GB, Fine PL, Fenves AZ, et al. (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. Journal of the American Society of Nephrology 12(6): 1164–72.

    PubMed  CAS  Google Scholar 

  53. Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral & Maxillofacial Surgery 61(9):1115–17.

    Article  Google Scholar 

  54. McCloskey E, Selby P, Davies M, Robinson J, et al. (2004) Clodronate reduces vertebral fracture in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study. JBMR 19(5):728–36.

    Article  CAS  Google Scholar 

  55. McClung MR, Geusens P, Miller PD, Zippel H, et al. (2001) Effect of risedronate on the risk of hip fracture in elderly women. NEJM 344(5):333–40.

    Article  PubMed  CAS  Google Scholar 

  56. Naessen T, Berglund L, Ulmsten U (1997) Bone loss in elderly women prevented by ultralow doses of parenteral 17 beta-estradiol. Am J Obstet Gynecol 177:115–19.

    Article  PubMed  CAS  Google Scholar 

  57. Orwoll E, Ettinger M, Weiss S, Miller P, et al. (2000) Alendronate for the treatment of osteoporosis in men. NEJM 343:604–10.

    Article  PubMed  CAS  Google Scholar 

  58. Pecherstorfer M, Ludwig H, Schlosser K, et al. (1996) Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. JBMR 11(5):587–93.

    CAS  Google Scholar 

  59. Peretz A, Body JJ, Dumon JC, et al. (1996) Cyclical pamidronate infusions in postmenopausal osteoporosis. Maturitas 25:69–75.

    Article  PubMed  CAS  Google Scholar 

  60. Pols HA, Felsenberg D, Hanley DA, et al. (1999) Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporosis International 9: 461–8.

    Article  PubMed  CAS  Google Scholar 

  61. Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG (2000) A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. JCEM 85:2197–202.

    PubMed  CAS  Google Scholar 

  62. Ravn P, Weiss SR, Rodriquez-Portales JA, McClung MR, et al. (2000) Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. JCEM 85(4):1492–7.

    PubMed  CAS  Google Scholar 

  63. Ravn P, Clemmesen B, Riis BJ, Christiansen C (1996) The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 19(5):527–33.

    Article  PubMed  CAS  Google Scholar 

  64. Recker RR, Stakkestad JA, Felsenberg D, et al. (2000) A new treatment paradigm: quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis: results of 3-year trial. Osteoporosis International 11(Suppl. 2):S209.

    Google Scholar 

  65. Reginster JY, Christiansen C, Roux C, et al. (2001) Intermittent cyclic tiludronate in the treatment of osteoporosis. Osteoporosis International 12(3):169–77.

    Article  PubMed  CAS  Google Scholar 

  66. Reginster JY, Minne HW, Sorensen O, Hooper M, Roux C, Brandi ML, et al. (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis International 11:83–91.

    Article  PubMed  CAS  Google Scholar 

  67. Reid IR, Brown JP, Burckhardt P, Horowitz Z, et al. (2002) Intravenous zoledronic acid in postmenopausal women with low BMD. NEJM 346(9):653–61.

    Article  PubMed  CAS  Google Scholar 

  68. Richelson LS, Wahner HW, Melton LJ, III, Riggs BL (1984) Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. NEJM 311: 1273–5.

    PubMed  CAS  Google Scholar 

  69. Riis BJ, Ise J, Von Stein T, et al. (2001) Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. JBMR 16(10): 1871–8.

    Article  CAS  Google Scholar 

  70. Riis BJ, Thomsen K, Strom V, Christiansen C (1987) The effect of percutaneous estradiol and progesterone on 150 Bone Resorption postmenopausal bone loss. Am J Obstet Gynecol 156: 61–5.

    PubMed  CAS  Google Scholar 

  71. Sorensen OH, Crawford GM, Mulder H, Hosking DJ, et al. (2003) Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience. Bone 32: 120–6.

    Article  PubMed  CAS  Google Scholar 

  72. Storm T, Thamsborg G, Steiniche T, et al. (1990) Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. NEJM 322:1265–71.

    PubMed  CAS  Google Scholar 

  73. Thiébaud D, Burckhardt P, Kriegbaum H, et al. (1997) Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. The American Journal of Medicine 103:298–307.

    Article  PubMed  Google Scholar 

  74. Valimaki M, Laitinen K, Patronen A, Puolijoki H, et al. (2002) Prevention of bone loss by clondronate in early postmenopausal women with vertebral osteopenia: a dose-finding study. Osteoporosis International 13: 937–47.

    Article  PubMed  CAS  Google Scholar 

  75. VanBeek E, Pieterman E, Cohen L, et al. (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491–4.

    Article  CAS  Google Scholar 

  76. Votta BJ, Levy MA, Badger A, Bradbeer J, et al. (1997) Peptide aldehyde inhibitors of cathepsin K inhibit bone resorption both in vitro and in vivo. JBMR 12:1396–406.

    Article  CAS  Google Scholar 

  77. Watts NB, Harris ST, Genant HK, et al. (1990) Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM 323(2):73–9.

    PubMed  CAS  Google Scholar 

  78. Wells G, Tugwell P, Shea B, Guyatt G, et al. (2002) Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrine Reviews 23(4):529–39.

    Article  PubMed  CAS  Google Scholar 

  79. Whyte MP, Wenkert D, Clements KL, McAllister WH, Mumm S (2003) Bisphosphonate-induced osteoporosis. NEJM 349(5):457–63.

    Article  PubMed  CAS  Google Scholar 

  80. The Women’s Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 291(14): 1701–12.

    Article  Google Scholar 

Download references

Authors
  1. Lorraine A. Fitzpatrick
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of BioStructure and Function, University of Connecticut Health Center, Farmington, CT, USA

    Felix Bronner PhD

  2. Department of Pharmacology, University of Connecticut Health Center, Farmington, CT, USA

    Felix Bronner PhD

  3. Department of Biology, University of Delaware, Newark, DE, USA

    Mary C Farach-Carson PhD

  4. Division of Endocrinology and Metabolism, Emory University School of Medicine, Veterans Affairs Medical Center, Decatur, GA, USA

    Janet Rubin MD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

Fitzpatrick, L.A. (2005). Pharmaceuticals for Bone Disease Targeting the Osteoclast. In: Bronner, F., Farach-Carson, M.C., Rubin, J. (eds) Bone Resorption. Topics in Bone Biology, vol 2. Springer, London. https://doi.org/10.1007/1-84628-016-8_8

Download citation

  • DOI: https://doi.org/10.1007/1-84628-016-8_8

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-812-1

  • Online ISBN: 978-1-84628-016-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation